Perioperative Ketamine for Pain With Gastric Bypass
NCT03448068 is a phase 2 interventional trial sponsored by Mayo Clinic. As of 18 Nov 2026, it is completed. It studies Ketamine and Standard Therapy in Ketamine and Laparoscopic Gastric Bypass Surgery. The registry lists an enrollment of 34 participants at 1 site in 1 country. The registry lists a start date of 16 Apr 2018 and a primary completion date of 9 Jan 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03448068 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Mayo Clinic |
| Enrollment | 34 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Ketamine and Laparoscopic Gastric Bypass Surgery |
| Drugs | Ketamine and Standard Therapy |
| Start | 16 Apr 2018 |
| Primary completion | 9 Jan 2020 |
| Study completion | 9 Jan 2020 |
| Last update posted | 29 Apr 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Andrew W Gorlin, M.D.
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Phoenix
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03448068
Each answer restates registry values shown on this page.
What is NCT03448068?
NCT03448068 is a phase 2 interventional trial sponsored by Mayo Clinic. It studies Ketamine and Standard Therapy in Ketamine and Laparoscopic Gastric Bypass Surgery.
Who leads NCT03448068?
The registry names Andrew W Gorlin, M.D. (principal investigator, Mayo Clinic) as the overall official.
Where does NCT03448068 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03448068 study?
The registered drug and biological interventions are Ketamine and Standard Therapy.
When did NCT03448068 end?
The registry lists a primary completion date of 9 Jan 2020 and a study completion date of 9 Jan 2020. The sponsor last updated the record on 29 Apr 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.